Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
Primary Purpose
Advanced Ovarian Cancer
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Neoadjuvant chemotherapy
Carboplatin
Sponsored by
About this trial
This is an interventional treatment trial for Advanced Ovarian Cancer
Eligibility Criteria
Inclusion Criteria:
- Advanced epithelial, tubal, or primary peritoneal cancer
- Cancer cells in paracentesis, thoracentesis, or laparoscopic surgery
- Less probability of complete cytoreduction
- Age: 20-80 years
- GOG performance status: 0-3
- Adequate organ function Bone marrow: ANC ≥ 1,500mm3, Platelet ≥ 100,000/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine ≤ 1.25 × UNL Liver: AST, ALT ≤ × 2.5 UNL (in case of liver metastasis, AST, ALT ≤ × 5 UNL), alkaline phosphatase ≤ 5 x UNL, bilirubin ≤ 1.5 mg/ mm3
Exclusion Criteria:
- Previous chemotherapy or pelvic radiation therapy
- Final diagnosis is other malignancies
- Coincidental Other malignancies within 5 years except carcinoma in situ of uterine cervix
- History of severe allergy
- Pregnancy, lactating woman
- Uncontrolled medial disease
- Bowel obstruction requiring immediate surgery
- Etc.
Sites / Locations
- Asan Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Chemotherapy
Arm Description
Neoadjuvant chemotherapy with docetaxel plus carboplatin
Outcomes
Primary Outcome Measures
Response rate
Secondary Outcome Measures
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Disease-free survival
Overall survival
The number of participants who achieved optimal cytoreduction
Full Information
NCT ID
NCT01462149
First Posted
October 25, 2011
Last Updated
May 27, 2017
Sponsor
Asan Medical Center
Collaborators
Sanofi
1. Study Identification
Unique Protocol Identification Number
NCT01462149
Brief Title
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
Official Title
Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Asan Medical Center
Collaborators
Sanofi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Neoadjuvant chemotherapy is alternative treatment option to upfront cytoreductive surgery to treat advanced ovarian cancer. Paclitaxel plus carboplatin is most frequently selected chemotherapeutic regimen for neoadjuvant chemotherapy. Docetaxel had similar therapeutic efficacy compared to paclitaxel in adjuvant chemotherapy trials in ovarian cancer. However, docetaxel had more favorable toxicity profile. Therefore, the investigators aimed to evaluate the efficacy of docetaxel plus carboplatin as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Ovarian Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Chemotherapy
Arm Type
Experimental
Arm Description
Neoadjuvant chemotherapy with docetaxel plus carboplatin
Intervention Type
Drug
Intervention Name(s)
Neoadjuvant chemotherapy
Intervention Description
Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Carboplatin AUC 5, q 3 weeks, 3 cycles
Primary Outcome Measure Information:
Title
Response rate
Time Frame
1 month after completion of study treatment
Secondary Outcome Measure Information:
Title
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame
Before each chemotherapy, an average of 3 week
Title
Disease-free survival
Time Frame
2 years after completion of study treatment
Title
Overall survival
Time Frame
2 years after completion of study treatment
Title
The number of participants who achieved optimal cytoreduction
Time Frame
1 month after completion of study treatment
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Advanced epithelial, tubal, or primary peritoneal cancer
Cancer cells in paracentesis, thoracentesis, or laparoscopic surgery
Less probability of complete cytoreduction
Age: 20-80 years
GOG performance status: 0-3
Adequate organ function Bone marrow: ANC ≥ 1,500mm3, Platelet ≥ 100,000/mm3, Hb ≥ 10.0 g/dl Kidney: Creatinine ≤ 1.25 × UNL Liver: AST, ALT ≤ × 2.5 UNL (in case of liver metastasis, AST, ALT ≤ × 5 UNL), alkaline phosphatase ≤ 5 x UNL, bilirubin ≤ 1.5 mg/ mm3
Exclusion Criteria:
Previous chemotherapy or pelvic radiation therapy
Final diagnosis is other malignancies
Coincidental Other malignancies within 5 years except carcinoma in situ of uterine cervix
History of severe allergy
Pregnancy, lactating woman
Uncontrolled medial disease
Bowel obstruction requiring immediate surgery
Etc.
Facility Information:
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
138-736
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
We'll reach out to this number within 24 hrs